Y.D. More Investments Ltd Sells 12,907 Shares of Pfizer Inc. (NYSE:PFE)

Key Points

• Y.D. More Investments Ltd reduced its stake in Pfizer Inc. by 38.8% in the first quarter, now owning 20,400 shares valued at approximately $517,000.
• Several institutional investors have recently altered their positions in Pfizer, with institutions owning 68.36% of the company's stock.
• Pfizer's stock performance includes a recent quarterly earnings report where it beat consensus estimates with earnings of $0.78 per share and revenue of $14.65 billion, showing a year-over-year revenue increase of 10.3%.

Y.D. More Investments Ltd lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 38.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,400 shares of the biopharmaceutical company's stock after selling 12,907 shares during the period. Y.D. More Investments Ltd's holdings in Pfizer were worth $517,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PFE. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares in the last quarter. North Capital Inc. purchased a new stake in Pfizer in the first quarter worth approximately $28,000. Bayforest Capital Ltd bought a new position in Pfizer during the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Pfizer during the fourth quarter worth approximately $30,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Wolfe Research increased their target price on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. HSBC reduced their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Finally, Jefferies Financial Group boosted their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Performance

NYSE:PFE opened at $24.25 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The stock has a market cap of $137.84 billion, a P/E ratio of 12.90, a price-to-earnings-growth ratio of 0.87 and a beta of 0.52. The firm's fifty day simple moving average is $24.42 and its 200 day simple moving average is $24.52.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the company earned $0.60 earnings per share. Pfizer's quarterly revenue was up 10.3% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer's payout ratio is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.